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type of management, age, duration of follow-up (F/U), 
relapse, rete testis invasion (RTI), and tumor size. Actu-
arial relapse-free survival curves were calculated for treat-
ment modalities and stratified for tumor sizes and RTI. A 
Cox regression model was calculated to explore for factors 
influencing relapses.
Results Disease-specific survival was 100 %. Crude 
relapse rates were 8.2, 2.4, 5.0, and 1.5 % for surveillance, 
radiotherapy, 1× Carboplatin, and 2× Carboplatin after a 
median F/U of 30 months. RTI and tumor size were not 
associated with progression in surveillance patients. One 
course Carboplatin caused relapses in 6.8 % in tumor sizes 
>4 cm and 9.3 % (actuarial 13 %) in sizes >5 cm. The Cox 
model revealed the association of tumor size with recur-
rence in the entire seminoma population (Hazard ratio 1.17; 
95 % confidence intervals 1.03–1.33).
Conclusions The overall outcome of CS1 seminoma 
managed on the routine care level mirrors that of controlled 
trials. Unexpectedly, the risk factors in surveillance patients 
were not confirmed, but tumor size proved to be a risk indi-
cator in the entire group of seminoma. Importantly, one 
course Carboplatin involved low efficacy to control the dis-
ease in large tumors.
Keywords Testicular seminoma · Carboplatin · 
Radiotherapy · Surveillance · Rete testis
Introduction
Clinical stage 1 (CS1) seminoma represents the most fre-
quent way of presentation of testicular germ cell tumors 
(GCTs) (Sokoloff et al. 2007; Heinzelbecker et al. 
2011). The overall survival rate of nearly 100 % can be 
achieved by three management options as recommended 
Abstract 
Purpose Clinical stage 1 (CS1) testicular seminoma 
involves an almost 100 % disease-specific survival in con-
trolled clinical trials. We aimed to find out whether these 
results can be matched in patients managed on the routine 
care level.
Patients, methods In total, 725 patients with seminoma 
CS1 were prospectively enrolled from 130 institutions. 
Adjuvant management as decided by local physicians 
involved surveillance (n = 256), radiotherapy (41), 1× 
Carboplatin (362), and 2× Carboplatin (66). We registered 
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in international guidelines (Albers et al. 2015; Oldenburg 
et al. 2013; Motzer et al. 2015). Currently, an expectant 
strategy with curative chemotherapy or radiotherapy to be 
applied only in the case of relapse is favored by European 
guidelines (Zengerling et al. 2013). A second option is 
adjuvant treatment with one course of Carboplatin AUC7 
in all of the cases. A third alternative is the risk-adapted 
strategy with adjuvant Carboplatin therapy in the pres-
ence of risk factors and watchful waiting in the absence 
of these factors (Aparicio et al. 2014; Beyer et al. 2013). 
In this setting, a tumor size of greater than 4 cm and the 
invasion of seminoma cells into the rete testis represent 
recognized indicators for progression (Warde et al. 2002). 
However, these factors have been a matter of concern ever 
since their introduction into clinical practice. In fact, no 
prospective validation study has been conducted so far. 
Particularly, rete testis invasion (RTI) lacked evidence in 
several studies (Ruf et al. 2013; Soper et al. 2014), while 
the significance of tumor size was supported repeatedly 
(Mortensen et al. 2014; Chung et al. 2015). When Carbo-
platin was introduced into the treatment of seminoma, the 
standard regimen consisted of two courses of the drug to be 
applied with 4 weeks apart (Oliver et al. 1990; Dieckmann 
et al. 1996). One course of Carboplatin was considered suf-
ficient according to a prospective randomized trial com-
paring abdominal radiotherapy with one course of Carbo-
platin where no inferiority of the drug regimen was found 
(Oliver et al. 2005). No formal comparative study has ever 
been conducted to prove the advantage of one course Car-
boplatin over the traditional two course regimen. Likewise, 
only three evaluations have supported the safety of the sin-
gle shot treatment to date (Tandstad et al. 2011; Chau et al. 
2015; Diminutto et al. 2015).
The present evaluation is a pattern of care analysis of 
CS1 seminoma patients in Germany (Dieckmann 2009). 
The first part of this project (National Seminoma Registry 
Study; NSR Study) had revealed surveillance to be cur-
rently the most frequently adopted management of semi-
noma patients (45 %) followed by the one course Carbo-
platin chemotherapy (35 %). Radiotherapy and the two 
courses regimen of Carboplatin are applied in less than 
10 % (Dieckmann et al. 2016). Here, we report the results 
of follow-up of the patients registered to the study. We eval-
uated the relapse rates in the four management modalities, 
and we also looked to the significance of risk factors with 
respect to disease progression.
Patients, methods
The principal aim of the present study was to analyze the 
treatment results in seminoma CS1 obtained in clinical 
routine practice (i.e., outside of clinical studies) with the 
treatment modalities that were endorsed by guidelines at the 
time of the study onset (Krege et al. 2008) and to compare 
these results with the data of high-standard controlled trials. 
During 2008–2013, a total of 1050 patients with testicular 
seminoma CS1 were registered from 130 institutions in Ger-
many (online resource 1). Informed consent was obtained 
from all individual participants included in the study. Ethical 
approval was given by Ärztekammer Hamburg (PV 3123). 
Follow-up (F/U) information is available in 725 patients, and 
this subcohort represents the database of the present analysis. 
The treatment decisions were solely made at the discretion 
of local institutions with no influence from study regulations. 
The quantitative distribution of the treatment groups thus 
reflects the current clinical practice in this country (Dieck-
mann et al. 2016). We registered the following parameters 
in each patient: age (years), mode of management, size of 
the primary tumor (cm), RTI (yes/no), time-point during F/U 
(months), relapse (yes/no), and unexpected event (specify). 
The primary endpoint of this study was the frequency of 
relapse in the four treatment modalities. The secondary end-
point was the association of the factors tumor size and RTI 
with relapse in the various treatment modalities.
Follow-up examinations were performed by local urol-
ogists according to current guidelines (Hartmann et al. 
2011). Results of the examinations were documented in a 
patient logbook with a copy of each report sent to the study 
center (Dieckmann 2009). In case of relapse, treatment was 
applied according to guidelines by local institutions (Krege 
et al. 2008).
All of the data were prospectively filed in a commercially 
available data base system (MS Excel). The final statistical 
analyses were performed with the SAS software package 
(version 9.3, SAS Institute, Inc., Cary, NC, USA) on a Win-
dows platform. Actuarial relapse rates of the four treatment 
modalities were calculated with generating Kaplan–Meier 
curves. The log-rank test was used to compare the relapse 
rates relating to the treatment methods. To explore the role 
of tumor size and RTI, a stratified analysis was separately 
performed on the groups with surveillance and 1× Carbo-
platin, respectively, by analyzing relapse rates in various 
subgroups. Also, a multivariate stratified analysis was per-
formed to look for combined effects of tumor size and RTI. 
Finally, a multivariate Cox regression model was calcu-
lated to establish Hazard ratios (HR) with 95 % confidence 
intervals (CIs) for relapse regarding the type of treatment, 
patient´s age, tumor size, and RTI. The chi-square test was 
used to compare Hazard ratios of the variables tested.
Results
Of the 725 eligible patients, 256 were managed by surveil-
lance, 41 with radiotherapy (20 Gy), 362 with one course 
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Carboplatin AUC7, and 66 with 2 courses Carboplatin. 
The median duration of F/U is 30 months (6–60 months). 
Clinical details are listed in Table 1. A total of 41 relapses 
were noted, and all except one relapse were detected upon 
F/U by imaging methods. Anatomically, 39 relapses were 
located in the retroperitoneum, and each one in the lungs, 
and bone. For treatment of relapsing disease, 8 patients 
received curative radiotherapy, 28 cisplatin-based chemo-
therapy, and two chemotherapy with additional surgery. In 
3 patients, the treatment of relapse is unknown (for more 
details, see online resource 2). All recurrences were cured 
generating a disease-specific survival rate of 100 %. Two 
patients (0.3 %) succumbed to unrelated events (1 cardiac 
event, 1 s malignancy). The relative proportions of recur-
rences in the treatment modalities are listed in Table 2. 
Kaplan–Meier curves showing the temporal course of the 
recurrences in each of the treatment modalities are pro-
vided in Fig. 1. The crude incidences of relapses among 
the four treatments are different though not statistically 
significant (log-rank, p = 0.0573). The majority of relapses 
developed within the first 2 years after primary treatment, 
but additional events occurred during the later course with 
the latest arising after 60 months in the surveillance group.  
In surveillance patients, stratified analyses for tumor size 
of greater or less than 4 cm and for RTI, respectively, did 
not reveal different relapses rates in the strata (Figs. 2, 3). 
Accordingly, a multivariate stratified analysis regarding the 
combined effect of tumor size and RTI failed to reveal any pre-
dictive value of these factors with respect to relapse (Fig. 4). 
By contrast, among patients undergoing one course of Carbo-
platin, tumor size of greater than 4 cm was significantly asso-
ciated (p = 0.0447) with relapse. Patients with tumors smaller 
than 4 cm relapsed in 2.3 % of cases (4 of 176) whereas 6.8 % 
(12 of 176) did so among those with tumors larger than 4 cm, 
resulting in a Hazard ratio of 3.03 (95 % CI 0.97–9.44) with 
respect to the progression risk of patients with tumors >4 cm. 
Further stratification of tumor size (Fig. 5) revealed that small 
tumors (<2 cm) had no relapse to date whereas those greater 
than 5 cm developed 9.3 % recurrences featuring an actuarial 
relapse rate of more than 13 % (p = 0.0296). Accordingly, 
relapse rates ranged around 3 % in the intermediate size cat-
egories. RTI was not associated with recurrence in this group 
(p = 0.1483). In a multivariate stratified analysis, looking for 
the combined effect of tumor size and RTI in the Carboplatin 
group, the highest relapse rate was found in patients with the 
two factors (9.1 %), but differences between subgroups were 
not significantly different.
Looking for factors influencing the recurrence of dis-
ease in the entire patient group, the Cox regression model 
adjusted for treatment mode revealed that size of the pri-
mary tumor involves a significantly increased Hazard rate 
of relapse of HR = 3.38 (95 % CI 1.10–10.41; p = 0.0338).
Table 1  Clinical details of the 
patients
Kruskal–Wallis test for comparison of ages and tumor sizes
Chi-square test for the presence of rete testis invasion (RTI), surveillance is the reference for comparison of 
groups
(n) Age (years) Tumor size (cm) RTI
Median Range Median >4 cm
Surveillance 256 40 20–75 2.5 25.3 % 17.5 %
Radiotherapy 41 39 25–65 4.4 68.3 % 7.4 %
Carboplatin 1× 362 42 19–82 4.0 49.0 % 65.8 %
Carboplatin 2× 66 43.5 21–81 4.0 50.0 % 9.3 %
p 0.86 <0.0001 <0.0001
Table 2  Relapse rates and 
duration of follow-up in the four 
treatment groups
DWD dead without disease, F/U follow-up
a Log-rank test for homogeneity of F/U duration
Surveillance Radiotherapy 1× Carboplatin 2× Carboplatin Total
n = 256 n = 41 n = 362 n = 66 n = 725
Relapse (n) 21 1 18 1 41
 Rate 8.2 % 2.4 % 5.0 % 1.5 % 5.7 %
 95 % CI 4.9–12.7 % 0.1–13.8 % 2.9–8.1 % 0–8.8 % 4.0–7.3 %
DWD 0 0 2 (0.6 %) 0 2 (0.3 %)
Median F/U (months) 24 36 30 30 30
Range of F/U (months) 6–60 6–60 0–60 6–60 0–60
p = 0.0573a
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Fig. 1  Time course of relapses 
in the four treatment modalities, 
Kaplan–Meier estimates
Fig. 2  Time course of relapses 
in surveillance patients, strati-
fied for tumor size, Kaplan–
Meier estimates
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Discussion
This study yielded five main results: (1) the overall treat-
ment results of seminoma CS1 are excellent on the level 
of clinical routine practice, (2) surveillance strategies can 
be used successfully in this setting, (3) rete testis invasion 
and tumor size failed as indicators for progression in sur-
veillance patients, (4) the one course Carboplatin regimen 
is less effective than expected, and (5) tumor size is predic-
tive of relapse in patients receiving one course Carboplatin.
With respect to the primary endpoint of the present 
study, a 100 % disease-specific survival rate was observed 
in seminoma CS1. Thus, the overall therapeutic outcome 
achieved in routine practice is identical with that reported 
from high-standard controlled trials (Mortensen et al. 2014; 
Cummins et al. 2010; Aparicio et al. 2014; Kollmanns-
berger et al. 2015; Oliver et al. 2011; Soper et al. 2014; 
Hallemeier et al. 2014).
Accordingly, the surveillance strategy proved to 
be safe on the routine practice level. Only 21 relapses 
(8.2 %) occurred in this cohort. This markedly low rate 
may be related to the low prevalence of the risk factors 
RTI (17.5 %) and tumor size >4 cm (25 %) in this cohort. 
Obviously, the majority of the surveillance patients had 
been selected for this management because of the absent 
risk indicators. In view of the low prevalence of these 
factors in our cohort, the relapse rate of 8.2 % com-
pares well with the rates of 8.3 % (Aparicio et al. 2014), 
9.5 % (Ondrusova et al. 2015), and 12.2 % (Warde et al. 
2002) reported for patients without risk factors. However, 
another reason for the comparatively low relapse rate is 
probably the rather short median observation time of 
24 months in this cohort. As 75 % of the relapses arise 
during the first 2 years of surveillance (Kollmannsberger 
et al. 2015; Mortensen et al. 2014; Soper et al. 2014), one 
may expect more recurrences to come in a longer obser-
vation period, which is also highlighted by the Kaplan–
Meier estimate of relapses of 13.5 % in our surveillance 
group.
It is of note that the recognized risk factors RTI and 
tumor size did not correlate with relapse in the surveillance 
cohort. However, selection bias could have contributed to 
this result because only less than one quarter of the patients 
in this subgroup had these factors. Nonetheless, those hav-
ing one or two of these factors did not relapse more fre-
quently than those without. Our report is thus in line with 
other series that failed to confirm RTI as a risk factor (Ruf 
et al. 2013; Chung et al. 2015).
Fig. 3  Time course of relapses 
in surveillance patients, 
stratified for rete testis invasion, 
Kaplan–Meier estimates
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Tumor size was not confirmed as a risk factor for pro-
gression in our surveillance cohort, and the same result 
was reported from a Japanese series (Kamba et al. 2010). 
Even so, this factor appears to be useful for predicting 
progression because the majority of previous studies had 
confirmed its validity (Chung et al. 2015; Mortensen et al. 
2014; Aparicio et al. 2014; Ruf et al. 2013) and, moreover, 
tumor size qualified as a risk marker even in patients under-
going adjuvant therapy (Cohn-Cedermark et al. 2015; Chau 
et al. 2015).
In the cohort with one course of Carboplatin, 18 relapses 
(5 %, 95 % CI 2.9–8.1 %) occurred and this result is in line 
with the previously reported rates of 5.1 % (Oliver et al. 
2011), 3.9 % (Tandstad et al. 2011), 4.0 % (Chau et al. 
2015), and 5.2 (Diminutto et al. 2015) in non-risk-adapted 
series. With two courses of Carboplatin, we observed a 
relapse rate of only 1.5 % (95 % CI 0–8.8 %). Although at 
first glance, two courses appear to be more efficacious than 
one course, the relapse rates of the two regimens are not 
statistically different (p = 0.2048). However possibly, the 
small sample size of our two course cohort (n = 66) could 
have prevented formal statistical significance. In fact, low 
relapse rates of 1.7 % (Steiner et al. 2011), 3.2 % (Aparicio 
et al. 2014), and 3.6 % (Koutsoukos et al. 2015) with two 
courses were reported recently, supporting the view that 
two courses of Carboplatin might be more efficacious than 
just one (Dieckmann et al. 2000).
Concerns regarding the effectivity of one course Carbo-
platin to eradicate micrometastatic seminoma is fueled by 
the unexpected high relapse rate of 9.3 % (Kaplan–Meier 
estimate 13.5 %) in the presence of tumor sizes of >5 cm. 
Although chance effects might have contributed to this 
result, this high recurrence rate is clearly inferior to the 
results obtained with adjuvant radiotherapy (Hallemeier 
et al. 2014) and with the two course Carboplatin treatment 
(Aparicio et al. 2014). Similar data have been reported 
from the Swenoteca trial, where relapses after 1× Carbo-
platin were detected in 2.7 % in the absence of risk factors 
and in as many as 9.4 % when one or two risk factors were 
present (Cohn-Cedermark et al. 2015). In a series from UK, 
tumor size as a continuous variable was significantly asso-
ciated with the relapse rate after 1× Carboplatin although 
the relapse rate was only slightly increased to 5.9 % in the 
patients with tumors larger than 4 cm (Chau et al. 2015). 
Likewise, 12.5 % relapses occurred with this regimen in the 
presence of risk factors in a small Slovakian series (Ondru-
sova et al. 2015).
Limitations of the present study derive from the lack 
of information regarding the applied dosages of Carbo-
platin. As dosing according to renal function is critical in 
Fig. 4  Time course of relapses 
in surveillance patients, strati-
fied for rete testis invasion and 
tumor size, Kaplan–Meier 
estimates
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the single shot Carboplatin regimen and dose reductions of 
10 % might considerably impact treatment outcome (Cath-
omas et al. 2014), some of the relapses of this study could 
have been caused by inadvertent underdosing of the drug. 
However, the effect of underdosing has been questioned 
recently (Diminutto et al. 2015). Moreover, the remark-
ably high relapse rate in the patients with large tumors does 
probably not solely relate to potential underdosing of Car-
boplatin because our results are statistically quite robust 
and support for the findings comes from other studies 
(Cohn-Cedermark et al. 2015; Ondrusova et al. 2015). One 
other limitation of the study relates to the lack of F/U infor-
mation in 325 of the 1050 patients originally enrolled. This 
markedly high proportion of lost patients may partly result 
from non-compliance of patients which is a well-known 
problem in young patients with GCT (Yu et al. 2009). 
Moreover, the lack of F/U information may also result from 
the German health system created fact that follow-up of 
patients is usually conducted by office urologists working 
independently of the institutions where the primary treat-
ment was done. According to the particular design of the 
study as a pattern of care analysis with no rigid trial regula-
tions, the study center had only minimal influence on par-
ticipating institutions and almost none on the office urolo-
gists performing the F/U examinations.
As shown in the Cox regression model, tumor size of 
>4 cm represents a risk factor not only in patients under 
surveillance but also in those undergoing single shot Car-
boplatin therapy. In light of a 25 % relapse rate usually 
experienced in patients with tumor size >4 cm under sur-
veillance (Warde et al. 2002), one course of Carboplatin 
reduced the anticipated relapse rates only by one half. This 
treatment is thus far less effective than expected from the 
pivotal studies (Oliver et al. 2011; Tandstad et al. 2011) and 
less effective than other adjuvant treatment modalities. The 
limited efficacy of Carboplatin in patients with large tumor 
sizes represents new knowledge that needs to be taken into 
account by upcoming guidelines. In practical terms, a plea 
could be made for applying two courses of the drug in 
patients with large tumors.
Acknowledgments The authors are grateful to 130 institutions in 
Germany (see online resource 1) for enrolling patients to this study.
Funding This study was funded by the “Hamburger Stiftung zur 
Förderung der Krebsbekämpfung” (Grant Nr. 180/2009).
Compliance with ethical standards 
Conflict of interest All of the authors declare that they have no con-
flict of interests.
Fig. 5  Time course of relapses 
in patients with one course 
Carboplatin, stratified for tumor 
sizes, Kaplan–Meier estimates
1606 J Cancer Res Clin Oncol (2016) 142:1599–1607
1 3
Ethical approval All procedures performed were in accordance 
with the ethical standards of the institutional research committee and 
the 1964 Helsinki Declaration and its later amendments. Formal ethi-
cal approval was given by Ärztekammer Hamburg (PV 3123).
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark 
G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J 
(2015) Guidelines on testicular cancer: 2015 update. Eur Urol 
68:1054–1068
Aparicio J, Maroto P, del Muro XG, Sánchez-Muñoz A, Gumà J, 
Margelí M, Sáenz A, Sagastibelza N, Castellano D, Arranz JA, 
Hervás D, Bastús R, Fernández-Aramburo A, Sastre J, Ter-
rasa J, López-Brea M, Dorca J, Almenar D, Carles J, Hernán-
dez A, Germà JR (2014) Prognostic factors for relapse in stage 
I seminoma: a new nomogram derived from three consecutive, 
risk-adapted studies from the Spanish Germ Cell Cancer Group 
(SGCCG). Ann Oncol 25:2173–2178
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, 
Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-
Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis 
M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, 
Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen 
S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, 
Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmanns-
berger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz 
JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Old-
enburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick 
O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer 
F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C 
(2013) Maintaining success, reducing treatment burden, focus-
ing on survivorship: highlights from the third European con-
sensus conference on diagnosis and treatment of germ-cell can-
cer. Ann Oncol 24(4):878–888
Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater 
M, Simmonds P, Nagaraj N, von Moos R, Fehr M (2014) Rel-
evant risk of carboplatin underdosing in cancer patients with nor-
mal renal function using estimated GFR: lessons from a stage I 
seminoma cohort. Ann Oncol 25(8):1591–1597
Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, 
Markham H, Lee C, Crabb SJ, Geldart T (2015) Treatment out-
come and patterns of relapse following adjuvant carboplatin for 
stage I testicular seminomatous germ cell tumour: results from a 
17 year UK experience. Ann Oncol 26(9):1865–1870
Chung P, Daugaard G, Tyldesley S, Atenafu EG, Panzarella T, Koll-
mannsberger C, Warde P (2015) Evaluation of a prognostic 
model for risk of relapse in stage I seminoma surveillance. Can-
cer Med 4(1):155–160
Cohn-Cedermark G, Stahl O, Tandstad TS (2015) Surveillance vs. 
adjuvant therapy of clinical stage I testicular tumors—a review 
and the SWENOTECA experience. Andrology 3(1):102–110
Cummins S, Yau T, Huddart R, Dearnaley D, Horwich A (2010) Sur-
veillance in stage I seminoma patients: a long-term assessment. 
Eur Urol 57:673–678
Dieckmann KP (2009) Seminoma clinical stage I: Still open ques-
tions? NSR study—a nationwide study of patterns of care. Uro-
loge A 48:419–422
Dieckmann KP, Krain J, Küster J, Brüggeboes B (1996) Adjuvant 
Carboplatin treatment for seminoma stage I. J Cancer Res Clin 
Oncol 122:63–66
Dieckmann K-P, Brüggeboes B, Pichlmeier U, Küster J, Müller-
leile U, Bartels H (2000) Adjuvant treatment of clinical stage I 
seminoma: Is a single course of carboplatin sufficient? Urology 
55:102–106
Dieckmann KP, Dralle-Filiz I, Heinzelbecker J, Matthies C, Bedke 
J, Ellinger J, Sommer J, Haben B, Souchon R, Anheuser P, 
Pichlmeier U (2016) Seminoma clinical stage 1—patterns of care 
in Germany. Urol Int. doi:10.1159/000443214. PMID:27092560 
[Epub ahead of print]
Diminutto A, Basso U, Maruzzo M, Morelli F, De Giorgi U, Perin A, 
Fraccon AP, Lo Re G, Rizzi A, Sava T, Fornarini G, Valcamonico 
F, Zustovich F, Massari F, Zanardi E, Roma A, Zattoni F, Zago-
nel V (2015) Adjuvant Carboplatin treatment in 115 patients with 
stage I seminoma: retrospective multicenter survey. Clin Geni-
tourin Cancer 14(2):e161–e169
Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, 
Pisansky TM (2014) Excellent long-term disease control with 
modern radiotherapy techniques for stage I testicular semi-
noma—the Mayo Clinic experience. Urol Oncol 32:24.e1–24.e6
Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cath-
omas R (2011) Nachsorge von Patienten mit Hodentumoren. 
Interdisziplinäre evidenzbasierte Empfehlungen [Follow-up of 
testicular germ cell cancer patients: interdisciplinary evidence-
based recommendations]. Urologe 50(7):830–835
Heinzelbecker J, Katzmarzik M, Weiss C, Trojan L, Michel MS, Hae-
cker A (2011) Changes of stage, predictive factors and adjuvant 
treatment modalities in seminomatous testicular cancer from 
1987 to 2007 and their impact on the status of metastasis, recur-
rence-free and overall survival: a single-center analysis. Urol Int 
87(3):282–287
Kamba T, Kamoto T, Okubo K, Teramukai S, Kakehi Y, Matsuda T, 
Ogawa O (2010) Outcome of different post-orchiectomy man-
agement for stage I seminoma: Japanese multi-institutional study 
including 425 patients. Int J Urol 17(12):980–987
Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, 
Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, 
Protheroe A, Tyldesley S, Black PC, Chi K, So AI, Moore MJ, 
Nichols CR (2015) Patterns of relapse in patients with clinical 
stage I testicular cancer managed with active surveillance. J Clin 
Oncol 33(1):51–57
Koutsoukos K, Tzannis K, Christodoulou C, Karavasilis V, Bakoyian-
nis C, Makatsoris T, Papandreou CN, Pectasides D, Dimopou-
los MA, Bamias A (2015) Two cycles of adjuvant carboplatin 
in stage I seminoma: 8-year experience by the Hellenic Coop-
erative Oncology Group (HECOG). World J Urol. Sept 26. 
PMID:26410826 [Epub ahead of print]
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, 
Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, 
Classen J, Clemm C, Cohn-Cedermark G, Culine S, Dau-
gaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, 
Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, 
Fizazi K, Flechon A, Fosså SD, Del Muro XG, Gauler T, 
Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann 
JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Hud-
dart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, 
Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, 
Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller 
R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, 
Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, 
1607J Cancer Res Clin Oncol (2016) 142:1599–1607 
1 3
Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmid-
berger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek 
NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weiss-
bach L, Wittekind C, Winter E, Wood L, von der Maase H 
(2008) European consensus conference on diagnosis and 
treatment of germ cell cancer: a report of the second meeting 
of the European Germ Cell Cancer Consensus group (EGC-
CCG): part I. Eur Urol 53:478–496
Mortensen MS, Lauritsen J, Gundgaard MG, Agerbæk M, Holm NV, 
Christensen IJ, von der Maase H, Daugaard G (2014) A nation-
wide cohort study of stage I seminoma patients followed on a 
surveillance program. Eur Urol 66:1172–1178
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, 
Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta 
S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine 
EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, 
Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch 
B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R (2015) 
Testicular cancer, version 2.2015. J Natl Compr Cancer Netw 
13(6):772–799
Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Boke-
meyer C, Horwich A, Beyer J, Kataja V, EGW Group (2013) 
Testicular seminoma and non-seminoma: ESMO Clinical Prac-
tice Guidelines for diagnosis, treatment and follow-up. Ann 
Oncol 24(Suppl 6):vi125–vi132
Oliver RTD, Lore S, Ong J (1990) Alternatives to radiotherapy in the 
management of seminoma. Br J Urol 65:61–67
Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe 
JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Sten-
ning SP, MTcatE Collaborators (2005) Radiotherapy versus sin-
gle-dose carboplatin in adjuvant treatment of stage I seminoma: 
a randomised trial. Lancet 366:293–300
Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, 
Gabe R, Pollock P, Stenning SP (2011) Randomized trial of 
carboplatin versus radiotherapy for stage I seminoma: mature 
results on relapse and contralateral testis cancer rates in MRC 
TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 
29(8):957–962
Ondrusova M, Ondrus D, Miskovska V, Kajo K, Szoldova K, Usakova 
V, Stastna V (2015) Management of clinical stage I testicular 
seminoma: active surveillance versus adjuvant chemotherapy. Int 
Urol Nephrol 47(7):1143–1147
Ruf CG, Khalili-Harbi N, Sachs S, Isbarn H, Wagner W, Matthies C, 
Meineke V, Fisch M, Chun FK, Abend M (2013) The search for 
biomarkers of metastatic seminoma. J Urol 190(3):1046–1051
Sokoloff MH, Joyce GF, Wise M, Urologic Diseases in America Pro-
ject (2007) Testis cancer. J Urol 177:2030–2041
Soper MS, Hastings JR, Cosmatos HA, Slezak JM, Wang R, Lodin 
K (2014) Observation versus adjuvant radiation or chemotherapy 
in the management of stage I seminoma: clinical outcomes and 
prognostic factors for relapse in a large US cohort. Am J Clin 
Oncol 37:356–359
Steiner H, Scheiber K, Berger AP, Rein P, Hobisch A, Aufderklamm J, 
Pilloni S, Stoehr B, Aigner F, Fritzer A, Zangerl F (2011) Retro-
spective multicentre study of carboplatin monotherapy for clini-
cal stage I seminoma. BJU Int 107(7):1074–1079
Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, 
Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, 
Dahl O, Cohn-Cedermark G (2011) Management of seminoma-
tous testicular cancer: a binational prospective population-based 
study from the Swedish Norwegian Testicular Cancer Study 
Group (SWENOTECA). J Clin Oncol 29(6):719–725
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarow-
icz M, Von Der Maase H (2002) Prognostic factors for relapse in 
stage I seminoma managed by surveillance: a pooled analysis. J 
Clin Oncol 20:4448–4452
Yu HY, Madison RA, Setodji CM, Saigal CS (2009) Quality of sur-
veillance for stage I testis cancer in the community. J Clin Oncol 
27(26):4327–4332
Zengerling F, Müller J, Schrader AJ, Schrader M (2013) Clinical 
stage I seminoma: Is surveillance a new therapy standard? Uro-
loge A 52(9):1265–1269 (Article in German)
